Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib or Trastuzumab + Nab-paclitaxel in HER2+ Breast Cancer
NCT04066790Phase 2Terminated
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Sep 2019; status: terminated.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04066790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04066790.